Catalyst

Slingshot members are tracking this event:

Daratumumab (DARZALEX) Granted Breakthrough Therapy Designation by U.S. FDA for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JNJ

100%

Additional Information

Additional Relevant Details Breakthrough Therapy Designation was granted to daratumumab based on data from two Phase 3 studies:
  • The MMY3004 (CASTOR) clinical trial evaluating daratumumab in combination with bortezomib and dexamethasone, compared to bortezomib and dexamethasone alone, in patients with multiple myeloma who received at least one prior therapy. Overall, the daratumumab combination therapy demonstrated a reduction in the risk of disease progression or death.
    • These results were presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) inJune 2016. More information can be found at www.ClinicalTrials.gov (NCT02136134).
  • The MMY3003 (POLLUX) clinical trial evaluating daratumumab in combination with lenalidomide and dexamethasone, compared to lenalidomide and dexamethasone alone, in patients with multiple myeloma who received at least one prior therapy. Overall, the addition of daratumumab reduced the risk of disease progression or death in these patients.
    • These results were presented at the 21st Annual Congress of the European Hematology Association (EHA) in June 2016. More information can be found at www.ClinicalTrials.gov (NCT02076009).
http://www.prnewswir...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 25, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Daratumumab, Darzalex, Breakthrough Therapy Designation, Multiple Myeloma, Dexamethasone, Bortezomib, Proteasome Inhibitor